I couldn’t believe it either.
A really good article released from GEN (Genetic Engineering and Biotechnology News) underscores an emerging trend in pharma pre-seed gap funding investment in R&D as an answer to a retraction of early stage VC from biotech and pharma sectors. One issue, how can you have a conversation about “Drugs” +”R&D”+”external partnerships” + “capital valley of death” and not mention the collaboration with research universities?!. It befuddles (always wanted to use that word) my mind. It was clearly an oversight in the complexity of the moment so I will append with a few words how this trend might intersect with research universities/gap funding. […]